AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Steven R. Altman has been elected to the company's Board of Directors effective immediately. Mr. Altman will serve on Amylin's Compensation and Human Resources Committee. "We are very pleased to welcome Steve to the Amylin Board," said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals. "He helps lead QUALCOMM Incorporated, a large, global technology business based in Southern California and brings extensive experience in licensing and technology acquisitions. He is also a strong patient advocate with children and other family members living with type 1 diabetes. Steve has committed personal resources to organizations pursuing new innovations in diabetes research and has informed us that he will contribute the compensation he receives from his Amylin board role to diabetes-related charities." Mr. Altman currently serves as President of QUALCOMM Incorporated. He joined QUALCOMM in 1989 as Corporate Counsel responsible for licensing and acquisitions, and was appointed Vice President and General Counsel in 1992. He became General Manager of QUALCOMM Technology Licensing (QTL) at the formation of the group in 1995 and was named Senior Vice President in 1996. In 1998, Mr. Altman was named Executive Vice President, then President of QTL in 2000 until his appointment as President of QUALCOMM in 2005. Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ware & Freidenrich, where he specialized in intellectual property, mergers and acquisitions, securities, and general corporate matters. He graduated from Northern Arizona University with a bachelor's degree in criminal justice and received his Juris Doctor from the University of San Diego School of Law. Mr. Altman is a member of the Board of Trustees of the Salk Institute. Mr. Altman is also a past board member of the San Diego chapter of the Juvenile Diabetes Research Foundation (JDRF) and currently is an active supporter of the JDRF. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development, and commercialization of innovative medicines. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director, Investor Relations, Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright